for appointments 716.250.2000

Current Research

If you would like to inquire about or participate in research projects at DENT, please contact us at 716-250-2038 for additional information. Below is a listing of our current studies.

ALZHEIMER’S RESEARCH

 AN2401-G000-201

 Need little reminders more often?

         

If you’re at least 50 years of age and have noticeable changes in your memory, judgment or ability to perform your daily activities, you may qualify for the BAN study. This study will evaluate an investigational drug for memory and thinking.

If you qualify, you’ll receive:

·         Study-related diagnostic procedures that may provide insight in to your thinking and memory issues,

·         Continuous medical monitoring of your condition,

·         Possible reimbursement for travel

 

For more information, contact:

Michelle Rainka, Pharm.D.: 716-250-2038

Amanda Jamison: 716-819-4117

 

 

HCA-MC-LZAX

Looking for something?

 

So are we – people with memory or thought processing problems.

·         Have you noticed a gradual decline in your memory?

·         Could you have mild Alzheimer’s disease?

·         Are you between 55 and 90 years of age?

If this sounds like you, consider EXPEDITION 3 – a clinical research study looking at investigational drug for mild Alzheimer’s disease. Study-related treatments and procedures will be free of charge.

 

For more information, contact:

Michelle Rainka, Pharm.D.: 716-250-2038

Amanda Jamison: 716-819-4117

Caroline Kumm: 716-250-2000 x4171

 

Additional Alzheimer’s research studies coming soon. Contact us for details!

Michelle Rainka, Pharm.D.: 716-250-2038

Amanda Jamison: 716-819-4117

Caroline Kumm: 716-250-2000 x4171

 

MULTIPLE SCLEROSIS RESEARCH

          Assess – Fingolimod

          Do you suffer from relapsing-remitting multiple sclerosis?

If you have relapsing-remitting multiple sclerosis (RRMS) and are between the ages of 18-65, you may want to join this study evaluating a new investigational drug that may help you reduce you relapses. Participation is voluntary. Qualified volunteers will receive study-related medical evaluations and study drug at no cost. Compensation for time and reasonable reimbursement for travel related expenses are available.

 

For more information, contact:

Michelle Rainka, Pharm.D.” 716-250-2038

Amanda Jamison: 716-819-4117

 

 

          PreferMS

Are you currently being treated for a relapsing remitting form of multiple sclerosis? If so,  you could be eligible to participate in a voluntary research study being conducted to evaluate different medications that treat relapsing remitting forms of multiple sclerosis.

 

To qualify for this study, you must:

·         Be between the ages of 18 and 65,

·         Have been diagnosed with a relapsing remitting form of MS

·         Are naïve to treatment; or have 5 years or less of total lifetime exposure to one class of Disease Modifying Therapy

 

Qualified participants will receive study-related exams and study medication at no cost.

 

For more information, contact:

Michelle Rainka, Pharm.D.: 716-250-2038

Amanda Jamison: 716-819-4117

Or visit www.rrmsresearchstudy.com

 

 

HEADACHE/MIGRAINE RESEARCH 

A Prospective, Observational Study for the Psychometric Evaluation of a Novel Migraine-Related Functional Impact Instrument in Episodic and Chronic Migraine

We are currently looking for people who experience migraines to participate in a research study that is looking at the association between your migraines and answers regarding symptoms, medication use and impact on your life recorded in an E-Diary.

To qualify for this study, you must:

  • Between 18-65 years of age
  • Have a history of migraines for 1 year or more prior to the study
  • Have at least 4 days of migraines per month for 3 months prior to the study
  • Meet other study eligibility criteria

If you qualify, compensation will be provided for study participation

Please contact 716-558-5670 if you are interested.

 

 

FORWARD Study: Evaluating preventive treatment options for Chronic Migraine

 To qualify for this study, you must:

  • Be between 18 to 65 years of age
  • Suffer from migraine
  • Have 15 or more dates with headache each month

 

If you are qualified you will receive at no cost to you study medication, study related care from a local doctor, compensation for your time for completed visits.

*Health insurance and physician referrals aren’t required to participate*

Please contact 716-558-5670 if you are interested.

 

Pathway CH-2 Cluster Headache Study

To qualify you must have been diagnosed with chronic cluster headache and have found preventive and/or acute cluster headache treatments to be inadequate for you.

To participate in this study you must:

  • Have been diagnosed with chronic cluster headache according to the 2013 ICHD criteria
  • Be at least 22 years of age
  • Suffer from at least 4 cluster attacks per week on the side where you typically feel attacks
  • Have judged, with your doctor, that previously or currently used medication treatment for your cluster headache are inadequate for you.
  • Be able to distinguish cluster attacks from other headaches such as migraine or tension-type headaches

 Please contact 716-558-5670 if you are interested.

 

A Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention

Primary Outcome Measures:

Change in monthly migraine days from baseline in the last 4 weeks of the 12-week double-blind treatment phase. Completion of double-blind treatment phase at 12 weeks.

To be eligible you must:

  • Be between the ages of 18 to 65
  • Have a history of at least 5 attacks of migraine without aura and/or migraine with visual sensory, speech and/or language, retinal or brainstem aura.
  • Have a history of ≥ 15 headache days per month of which ≥ 8 headache days were assessed by the subject as migraine day.

You will be compensated for your time and travel for this study.

If you are interested in participating in this trial please call 716-558-5670.

 

Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds

Study Objectives:

The primary objective is to characterize the pharmacokinetics of a single oral administration of 50 mg Cambia in pediatric subjects, ages 12-17 years with a diagnosis of episodic migraine with or without aura.

  • To be eligible you must:
  • Be between the ages of 12 to 17 years old
  • Have a diagnosis of episodic migraine with or without aura for at least 3 months prior to screening
  • Have 14 or fewer headache days per month

 

You will be compensated for your time and travel for this study.

If you are interested in participating in this trial please call 716-558-5670.

 

TREXIMET Aura Clinical Trial

Sponsored by Laszlo L. Mechtler, M.D.

A parallel two arm, double blinded placebo study, examining the efficacy of Sumatriptan with Naprosyn in the treatment of migraine with aura.

Qualified participants will be:

  • 18 to 50 years of age, inclusive
  • Carry a diagnosis of 1-2 migraine with aura per month for at least three months before study inclusion
  • Have an onset of a visual aura that occurs 15-30 minutes before a migraine headache
  • Able to understand and complete a migraine diary
  • In generally good health as confirmed by medical and medication history
  • Female subjects must be either a) postmenopausal for one year, b) surgically sterile, c)on acceptable birth control for at least 1 month prior to screening and throughout the study, or d) practicing abstinence and agree to continue same throughout study.

FOR MORE INFORMATION CONTACT: Rebecca Hogan, Clinical Research Coordinator: 716-558-5670

  

TREXIMET Aura Clinical Trial

Sponsored by Laszlo L. Mechtler, M.D.

A parallel two arm, double blinded placebo study, examining the efficacy of Sumatriptan with Naprosyn in the treatment of migraine with aura.

Qualified participants will be:

  • 18 to 50 years of age, inclusive
  • Carry a diagnosis of 1-2 migraine with aura per month for at least three months before study inclusion
  • Have an onset of a visual aura that occurs 15-30 minutes before a migraine headache
  • Able to understand and complete a migraine diary
  • In generally good health as confirmed by medical and medication history
  • Female subjects must be either a) postmenopausal for one year, b) surgically sterile, c)on acceptable birth control for at least 1 month prior to screening and throughout the study, or d) practicing abstinence and agree to continue same throughout study.

FOR MORE INFORMATION CONTACT:
Olga I. Ananina, Clinical Research Coordinator: 716-558-5670

 

BRAIN TUMOR/ONCOLOGY RESEARCH

More Studies Coming Soon !

FOR MORE INFORMATION CONTACT:
 Rebecca Hogan, Clinical Research Coordinator: 716-558-5670